Modification of piracetam’s nootropic action by phenibut, Bemitil and Sydnocarb
Comparison in people · 2004
- What was studied
- Several animal and human experiments; human study settings separated in the program table
- Main finding
- Piracetam combinations were tested with Bemitil, phenibut or sydnocarb. In animals, the author describes a narrow range of supra-additivity, additive or antagonistic effects at other ratios, and faster Bemitil elimination with piracetam.
Piracetam + Bemitil · experimental interaction · Supra-additivity reported with Bemitil at 16–30% of total formulation mass · The dissertation reports additive effects outside that window and possible partial antagonism with further dose escalation. Animal hypoxia findings.
Related evidence maps: Military & occupational ↗
Reported findings and study design
122-page dissertation supervised by E. B. Shustov, with separate animal models, human experiments and pharmacokinetic observations.
Population or model Several animal and human experiments; human study settings separated in the program table
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Piracetam + Bemitil · experimental interaction | Supra-additivity reported with Bemitil at 16–30% of total formulation mass | The dissertation reports additive effects outside that window and possible partial antagonism with further dose escalation. Animal hypoxia findings. |
| Bemitil elimination | Approximately twice as fast when co-administered with piracetam | Author-reported pharmacokinetic conclusion; underlying estimates, sampling and model require the original tables. |
| Animal swim experiment | Piracetam 90 mg/kg: +25%; Bemitil 37.5 mg/kg: +45% | Author conclusions; separate tested doses, not a clinical comparison. |
| Other formulations | Pirafen: piracetam + phenibut; Pirasid: piracetam + sydnocarb | Distinct preparations and task-dependent results. The excerpt does not establish a universal benefit. |
| Human performance evidence | Group-level estimates and complete allocation not recovered | Separate studies within the dissertation; no basis for a clinical regimen. |
An interaction can change direction with dose and endpoint. The animal and pharmacokinetic observations do not validate a human combination.
Source for these results ↗ · Reviewed 2026-11-08
Study limitations and source details
Study limitations
- Experiments within one dissertation are not independent program replication.
- OCR gaps, small groups and incomplete allocation details limit appraisal.
- Combination exposure changes do not establish clinical synergy.
Related publications may describe some of the same participants or experiments.
Source details
Dissertation transcription · Author’s-abstract transcription
Dissertation excerpt and conclusions checked against the earlier source record; exact original interaction and pharmacokinetic tables not recovered.
Selected methods, ratio-dependent findings and pharmacokinetic conclusions
Sources checked
Citation
A. E. Kim. Modification of piracetam’s nootropic action by phenibut, Bemitil and Sydnocarb Candidate dissertation author’s abstract, Saint Petersburg, 2004
Related compounds
Pirabel
An experimental formulation combining piracetam and Bemitil, studied in Russian fatigue research.
Piracetam
A synthetic compound in the racetam family, also known by the brand Nootropil. It appears in neurological research and historical fatigue-related combination studies.
Bemitil
A synthetic benzimidazole derivative also called bemethyl or Metaprot. Soviet and Russian researchers studied it as an actoprotector, a drug intended to preserve physical work capacity under stress.